Table A1.
EP Trials With the Highest NCCCP Accrual (July 2010-June 2011)
| Trial ID | Phase | Cancer | Stage | Intervention | Lead Organization | Sponsor | Accrual from NCCCP Sites* |
|---|---|---|---|---|---|---|---|
| NCT01106898 | II | Breast | I-II | Adjuvant cyclophosphamide, paclitaxel ± trastuzumab | University of Nebraska | NCI-designated cancer center | 23 |
| NCT00861705 | II | Breast | II-III, ER/PR poor, HER2 negative | Neoadjuvant addition of carboplatin ± bevacizumab to weekly paclitaxel followed by dose-dense doxorubicin/cyclophosphamide | CALGB | NCI | 17 |
| NCT00828841 | II | Lung non–small-cell | IIIb-IV/relapsed | Cetuximab + platinum-based chemotherapy | Accelerated Community Oncology Research Network | Industry | 16 |
| NCT00881361 | II | Breast | II-III | Sentinel node surgery and axillary node dissection following neoadjuvant chemotherapy | ACOSOG | NCI | 12 |
| NCT00614822 | II | Lung non–small-cell | IIIb-IV | Carboplatin, bevacizumab and pemetrexed | Christiana Care Health Services/ Eli Lilly | Industry | 11 |
| NCT01295723 | I | Breast | I | Intraoperative boost radiotherapy with electrons followed by hypofractionated whole-breast radiation | St. Joseph Hospital of Orange | Institutional | 11 |
| NCT00986674 | II | Lung non–small-cell | IIIb-IV | Carboplatin and paclitaxel in combination with cetuximab, insulin-like growth factor 1 receptor antibody IMC-A12 or both | ECOG | NCI | 10 |
| NCT00928174 | I/II | Prostate | Androgen insensitive | Measurement of anti-androgen response with 18F-choline PET/CT in androgen insensitive prostate cancer | Queen's Medical Centre | Institutional/NCI | 10 |
| NCT00887159 | II | Lung small-cell | Extensive | Cisplatin and etoposide + hedgehog inhibitor GDC-0449 or insulin-like growth factor 1 receptor antibody IMC-A12 | ECOG | NCI | 9 |
| NCT00603863 | I/II | Pancreatic | III-IV | Fractionated 90Y-labeled anti-mucin humanized antibody (90Y-hPAM4) + gemcitabine | Immunomedics | Industry | 9 |
Abbreviations: ACOSOG, American College of Surgeons Oncology Group; CALGB, Cancer and Leukemia Group B; ECOG, Eastern Cooperative Oncology Group; EP, early-phase; ER, estrogen receptor; HER, human epidermal growth factor receptor; NCCCP, National Cancer Institute Community Cancer Centers Program; NCI, National Cancer Institute; NCT, ClinicalTrials.gov identifier; PR, progesterone receptor.
*
Accrual shown is from NCCCP sites participating in the BA.